Moderate-Intensity Rosuvastatin Plus Ezetimibe Versus High-Intensity Rosuvastatin for Target Low-Density Lipoprotein Cholesterol Goal Achievement in Patients With Recent Ischemic Stroke: A Randomized Controlled Trial
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Purpose Moderate-intensity statin plus ezetimibe versus high-intensity statin alone may provide a greater low-density lipoprotein cholesterol (LDL-C) reduction in patients with recent ischemic stroke.Methods This randomized, open-label, controlled trial assigned patients with recent ischemic stroke <90 days to rosuvastatin/ezetimibe 10/10 mg once daily (ROS10/EZT10) or to rosuvastatin 20 mg once daily (ROS20). The primary endpoint was LDL-C reduction ≥50% from baseline at 90 days. Key secondary endpoints were LDL-C <70 mg/dL and multiple lipid goal achievement, and composite of major vascular events.Results Of 584 randomized, 530 were included in the modified intention-to-treat analysis. The baseline LDL-C level was 130.2±34.7 mg/dL in the ROS10/EZT10 group and 131.0±33.9 mg/dL in the ROS20 group. The primary endpoint was achieved in 198 patients (72.5%) in the ROS10/EZT10 group and 148 (57.6%) in the ROS20 group (odds ratio [95% confidence interval], 1.944 [1.352–2.795]; <i>P</i>= 0.0003). LDL-C level <70 mg/dL was achieved in 80.2% and 65.4% in the ROS10/EZT10 and ROS20 groups (<i>P</i>=0.0001). Multiple lipid goal achievement rate was 71.1% and 53.7% in the ROS10/EZT10 and ROS20 groups (<i>P</i><0.0001). Major vascular events occurred in 1 patient in the ROS10/EZT10 group and 9 in the ROS20 group (<i>P</i>=0.0091). The adverse event rates did not differ between the two groups.Conclusion Moderate-intensity rosuvastatin plus ezetimibe was superior to high-intensity rosuvastatin alone for intensive LDL-C reduction in patients with recent ischemic stroke. With the combination therapy, more than 70% of patients achieved LDL-C reduction ≥50% and 80% had an LDL-C <70 mg/dL at 90 days.
Abstract
Background and Purpose Moderate-intensity statin plus ezetimibe versus high-intensity statin alone may provide a greater low-density lipoprotein cholesterol (LDL-C) reduction in patients with recent ischemic stroke.Methods This randomized, open-label, controlled trial assigned patients with recent ischemic stroke <90 days to rosuvastatin/ezetimibe 10/10 mg once daily (ROS10/EZT10) or to rosuvastatin 20 mg once daily (ROS20). The primary endpoint was LDL-C reduction ≥50% from baseline at 90 days. Key secondary endpoints were LDL-C <70 mg/dL and multiple lipid goal achievement, and composite of major vascular events.Results Of 584 randomized, 530 were included in the modified intention-to-treat analysis. The baseline LDL-C level was 130.2±34.7 mg/dL in the ROS10/EZT10 group and 131.0±33.9 mg/dL in the ROS20 group. The primary endpoint was achieved in 198 patients (72.5%) in the ROS10/EZT10 group and 148 (57.6%) in the ROS20 group (odds ratio [95% confidence interval], 1.944 [1.352–2.795]; <i>P</i>= 0.0003). LDL-C level <70 mg/dL was achieved in 80.2% and 65.4% in the ROS10/EZT10 and ROS20 groups (<i>P</i>=0.0001). Multiple lipid goal achievement rate was 71.1% and 53.7% in the ROS10/EZT10 and ROS20 groups (<i>P</i><0.0001). Major vascular events occurred in 1 patient in the ROS10/EZT10 group and 9 in the ROS20 group (<i>P</i>=0.0091). The adverse event rates did not differ between the two groups.Conclusion Moderate-intensity rosuvastatin plus ezetimibe was superior to high-intensity rosuvastatin alone for intensive LDL-C reduction in patients with recent ischemic stroke. With the combination therapy, more than 70% of patients achieved LDL-C reduction ≥50% and 80% had an LDL-C <70 mg/dL at 90 days.
참고문헌 (25)
- Amarenco P, "Lipid management in the prevention of stroke : review and updated meta-analysis of statins for stroke prevention", Lancet Neurol, 8, pp.453~463 (2009)
- Shin J, "Achieved low-density lipoprotein cholesterol level and stroke risk : a meta-analysis of 23 randomised trials", Eur J Prev Cardiol, 28, pp.905~916 (2021)
- Catapano AL, "2016 ESC", EAS guidelines for the management of dyslipidaemias, 2016, pp.37, 2999~3058
- Kleindorfer DO, "2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack : a guideline from the American Heart Association", American Stroke Association, 2021, pp.52, e364~e467
- Alsheikh-Ali AA, "Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials", J Am Coll Cardiol, 50, pp.409~418 (2007)
- Baigent C, "Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials", Lancet, 376, pp.1670~1681 (2010)
- Preiss D, "Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy : a meta-analysis", JAMA, 305, pp.2556~2564 (2011)
- Nicholls SJ, "Metaanalysis of comparative efficacy of increasing dose of atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids(from VOYAGER)", Am J Cardiol, 105, pp.69~76 (2010)
- Sabatine MS, "Evolocumab and clinical outcomes in patients with cardiovascular disease", N Engl J Med, 376, pp.1713~1722 (2017)
- Giugliano RP, "Long-term safety and efficacy of achieving very low levels of low-density lipoprotein cholesterol : a prespecified analysis of the IMPROVE-IT trial", JAMA Cardiol, 2, pp.547~555 (2017)
- Giugliano RP, "Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab : a prespecified secondary analysis of the FOURIER trial", Lancet, 390, pp.1962~1971 (2017)
- Cannon CP, "Ezetimibe added to statin therapy after acute coronary syndromes", N Engl J Med, 372, pp.2387~2397 (2015)
- Van Heek M, "In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461", J Pharmacol Exp Ther, 283, pp.157~163 (1997)
- Morrone D, "Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000subjects from 27 clinical trials", Atherosclerosis, 223, pp.251~261 (2012)
- Ambegaonkar BM, "Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis", Atherosclerosis, 237, pp.829~837 (2014)
- Stone NJ, "2013 ACC", AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults : a report of the American College of Cardiology, Circulation, pp.2014, 129(25 Suppl 2)[DOI]
- Kernan WN, "Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack : a guideline for healthcare professionals from the American Heart Association", American Stroke Association, 2014, pp.45, 2160~2236
- Jellinger PS, "American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease", Endocr Pract, 23(Suppl 2), pp.1~87 (2017)
- Krupp LB, "The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus", Arch Neurol, 46, pp.1121~1123 (1989)
- Kim KJ, "Effect of fixed-dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia : MRSROZE(Multicenter Randomized Study of ROsuvastatin and eZEtimibe)", Cardiovasc Ther, 34, pp.371~382 (2016)
- Kim BK, "Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial", Lancet, 400, pp.380~390 (2022)
- Amarenco P, "A comparison of two LDL cholesterol targets after ischemic stroke", N Engl J Med, 382, pp.9~19 (2020)
- Amarenco P, "Yield of dual therapy with statin and ezetimibe in the Treat Stroke to Target trial", Stroke, 53, pp.3260~3267 (2022)
- 허지회, "Effect and Safety of Rosuvastatin in Acute Ischemic Stroke", 대한뇌졸중영문학회지, 18(1), pp.87~95 (2016), 대한뇌졸중학회
- Tamargo J, "Racial and ethnic differences in pharmacotherapy to prevent coronary artery disease and thrombotic events", Eur Heart J Cardiovasc Pharmacother, 8, pp.738~751 (2022)